Transmembrane protease serine 5 (TMPRSS5)

TMPRSS5, also known as transmembrane protease serine 5 or spinesin, is a type II transmembrane serine protease encoded by the TMPRSS5 gene on chromosome 11q23[1][3]. It has a domain architecture consisting of a short cytoplasmic segment, a single transmembrane domain, a stem region with a scavenger receptor-like domain, and an extracellular serine protease catalytic domain containing the classical catalytic triad (His, Asp, Ser)[3]. TMPRSS5 shows the highest mRNA and protein expression in the nervous system, especially in neurons and Schwann cells, where it localizes to axons and synapses[3]. Biochemically, it exhibits trypsin-like proteolytic activity. Functionally, TMPRSS5 (spinesin) appears to play roles in neural function and maintenance, including at synapses and possibly in oligodendrocytes[3]. Clinically, elevated plasma levels of TMPRSS5 are a robust biomarker for Charcot-Marie-Tooth disease type 1A (CMT1A), showing strong sensitivity and specificity for this neuropathy across patient cohorts; however, it is not currently targeted by any known therapeutics nor widely used as a safety or efficacy biomarker outside CMT1A research[2]. If more drug interaction, mechanism of action, or safety information becomes available, this entry can be updated. There is no evidence of a misspelling or incorrect target identity.

Other names

Spinesintransmembrane serine protease 5MGC141886MGC148044